IP Verse

Treatment For Bone Diseases - EP2869844

The patent EP2869844 was granted to UCB Pharma on Jun 21, 2023. The application was originally filed on Jul 3, 2013 under application number EP13733322A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2869844

UCB PHARMA
Application Number
EP13733322A
Filing Date
Jul 3, 2013
Status
Patent Maintained As Amended
May 19, 2023
Grant Date
Jun 21, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLESep 18, 2020CARPMAELS & RANSFORDWITHDRAWN

Patent Citations (32) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2008US86864
DESCRIPTIONUS2004009535
DESCRIPTIONUS2004158045
DESCRIPTIONUS2005106683
DESCRIPTIONUS2005238646
DESCRIPTIONUS2007072797
DESCRIPTIONUS2007110747
DESCRIPTIONUS5399363
DESCRIPTIONUS5466468
DESCRIPTIONUS5543158
DESCRIPTIONUS5641515
DESCRIPTIONUS6395511
DESCRIPTIONUS6703199
DESCRIPTIONUS6803453
DESCRIPTIONUS7592429
DESCRIPTIONUS7744874
DESCRIPTIONUS8003108
DESCRIPTIONUS8017120
DESCRIPTIONWO2008092894
DESCRIPTIONWO2008115732
DESCRIPTIONWO2009047356
DESCRIPTIONWO2009056634
DESCRIPTIONWO2010100179
DESCRIPTIONWO2010100200
DESCRIPTIONWO2010115932
DESCRIPTIONWO2010130830
INTERNATIONAL-SEARCH-REPORTUS2007110747
INTERNATIONAL-SEARCH-REPORTWO2008115732
INTERNATIONAL-SEARCH-REPORTWO2009047356
INTERNATIONAL-SEARCH-REPORTWO2009079471
INTERNATIONAL-SEARCH-REPORTWO2010130830
OPPOSITIONUS2007110747

Non-Patent Literature (NPL) Citations (20) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- C V Winder ET AL, "On the nature of tachyphylaxis and related phenomena", Fed. Proc., (19480101), vol. 7, no. 1, page 136, XP055516898
EXAMINATION- VAN ASSCHE G ET AL, "Management of loss of response to anti-TNF drugs: Change the dose or change the drug?", JOURNAL OF CROHN'S AND COLITIS, ELSEVIER BV, NL, vol. 2, no. 4, doi:10.1016/J.CROHNS.2008.05.011, ISSN 1873-9946, (20081201), pages 348 - 351, (20080828), XP025692421
EXAMINATION- U. Kopylov ET AL, "The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab : Efficacy of infliximab dosing once in 6?weeks", ALIMENTARY PHARMACOLOGY & THERAPEUTICS., GB, (20101201), vol. 33, no. 3, doi:10.1111/j.1365-2036.2010.04523.x, ISSN 0269-2813, pages 349 - 357, XP055516755
EXAMINATION- Farzin Forooghian ET AL, "Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis", Acta Ophthalmologica: the ophthalmological journal of the Nordic countries, Denmark, (20110223), vol. 89, no. 2, doi:10.1111/j.1755-3768.2009.01773.x, ISSN 1755-375X, pages e206 - e207, XP055516906
EXAMINATION- PAUL D. MILLER, "A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis", THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, (20111201), vol. 3, no. 6, doi:10.1177/1759720X11424220, pages 271 - 282, XP055515647
OPPOSITION- Anonymous, "History of Changes for Study: NCT00896532 Phase 2 Study of AMG 785 in Postmenopausal Women With Low Bone Mineral Density", clinical trial protocol NCT00896532, (20090507), URL: https://clinicaltrials.gov/ct2/history/NCT00896532?V_1=View#StudyPageTop, XP055741867
OPPOSITION- EMA, "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)", EMA - News, (20190625), URL: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019, XP055741888
OPPOSITION- EMA, "Summary of opinion (initial authorisation) Evenity romosozumab", EMA/546072/2019, (20191017), XP055741896
OPPOSITION- FINKELSTEIN et al., "Effects of Teriparatide Retreatment in Osteoporotic Men and Women", J. Clin. Endocrinol. Metab., (20090701), vol. 94, no. 7, pages 2495 - 2501
OPPOSITION- KE H. Z. et al., "Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases", Endocrine Reviews, (20121001), vol. 33, no. 5, pages 747 - 783
OPPOSITION- MILLER P. D., "Denosumab: Anti-RANKL antibody", Current Osteoporosis Reports, (20090301), vol. 7, no. 7, pages 18 - 22
OPPOSITION- PADHI D. et al., "OC17 Effects of multiple doses of the sclerostin antibody AMG 785 in healthy men and postmenopausal women with low bone mass", ECTS 2012, 39th Annual congress, Stockholm, Sweden, (20120519), pages S34 - S35
OPPOSITION- WARMINGTON et al., "Increases in BMD Observed with Anti-Sclerostin Antibody Treatment Are Reversible: A LongitudinalOvariectomized Rat Study", 30th Annual Meeting American Society for Bone and Mineral Research, Montreal Quebec, Canada, (20080915), URL: https://www.abstractsonline.com/viewer/viewAbstract.asp?CKey={1F2186AE-5565-4015-9DC3-848276FA1179}&MKey={DCB70C83-5B38-431A-B0E1-9221D66718D0}&AKey={D0C01D4F-E23B-45E2-ACD4-0AF8AC866B8B}&SKey={573C1565-EC04-476F-BBF0-182DD52FC667}
OPPOSITION- WARMINGTON et al., "Increases in BMD Observed with Anti-Sclerostin Antibody Treatment Are Reversible: A LongitudinalOvariectomized Rat Study", 30th Annual Meeting American Society for Bone and Mineral Research, Montreal Quebec, Canada, (20080915), URL: https://www.abstractsonline.com/viewer/viewAbstract.asp?CKey={1F2186AE-5565-4015-9DC3-848276FA1179}&MKey={DCB70C83-5B38-431A-B0E1-9221D66718D0}&AKey={D0C01D4F-E23B-45E2-ACD4-0AF8AC866B8B}&SKey={573C1565-EC04-476F-BBF0-182DD52FC667}, XP055741883
OPPOSITION- WATTS et al., "American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis", Endocr. Pract., (20101100), vol. 16, no. Suppl 3, pages 1 - 37
OPPOSITION- MILLER P. D., "Denosumab: Anti-RANKL antibody", Current Osteoporosis Reports, (20090301), vol. 7, no. 7, pages 18 - 22, XP055038533
OPPOSITION- PADHI D. et al., "OC17 Effects of multiple doses of the sclerostin antibody AMG 785 in healthy men and postmenopausal women with low bone mass", ECTS 2012, 39th Annual congress, Stockholm, Sweden, (20120519), pages S34 - S35, XP028922309
OPPOSITION- KE H. Z. et al., "Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases", Endocrine Reviews, (20121001), vol. 33, no. 5, pages 747 - 783, XP055741862
OPPOSITION- FINKELSTEIN et al., "Effects of Teriparatide Retreatment in Osteoporotic Men and Women", J. Clin. Endocrinol. Metab., (20090701), vol. 94, no. 7, pages 2495 - 2501, XP055741857
OPPOSITION- WATTS et al., "American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis", Endocr. Pract., (20101100), vol. 16, no. Suppl 3, pages 1 - 37, XP055741858

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents